menu
    • menu
    [{"orgOrder":0,"company":"Currax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Phenazon","moa":"Cyclooxygenase-1","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Currax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Currax \/ Undisclosed"},{"orgOrder":0,"company":"Global United Pharmaceutical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Phenazon","moa":"Cyclooxygenase-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Global United Pharmaceutical Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global United Pharmaceutical Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Global United Pharmaceutical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Renascience Pharma","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Phenazon","moa":"||Cyclooxygenase-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Renascience Pharma","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"Renascience Pharma \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Renascience Pharma \/ Lupin Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals for Prestwick3_000029

    Menu

    Prestwick3_000029

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Renascience Pharma

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Renascience Pharma

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Phenazon,Lidocaine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : $15.9 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lupin announces acquisition of UK-Based Renascience Pharma for GBP 12.3 mn

                            Details : Through the acquisition, Lupin will leverage Renascience key products, which includes Otigo (phenazone/lidocaine HCl) for pain due to acute otitis media.

                            Product Name : Otigo

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 03, 2025

                            Lead Product(s) : Phenazon,Lidocaine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : $15.9 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Global United Pharmaceutical Corporation

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Global United Pharmaceutical Corporation

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Phenazon

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults

                            Details : Antipyrine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 03, 2014

                            Lead Product(s) : Phenazon

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Currax

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Currax

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Phenazon

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media

                            Details : Antipyrine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Otitis Media.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 16, 2014

                            Lead Product(s) : Phenazon

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth